Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms

Table 5 Details of instrument output discrepancies with statistical significance

Biomarker	Instruments	Mean 1 (pg/mL)	Mean 2 (pg/mL)	∆ (pg/mL)	% Difference^a (%)	95% CI (pg/mL)	P-value, adjusted^†
ApoE	200 vs FM3D	819.5	796.1	22.4	2.8	4.6 to 40.1	0.0107
MMP-9	MPX vs 200	166.7	175.1	− 8.4	5.0	− 14.0 to − 2.9	0.0020
	MPX vs FM3D	166.7	174.1	− 7.4	4.4	− 14.0 to − 0.8	0.0261
SDC1	MPX vs 200	13,986.0	13,690.0	295.3	2.2	91.9 to 498.8	0.0031
	200 vs FM3D	13,690.0	13,991.0	− 301.1	2.2	− 494.2 to − 108.1	0.0015

^aDifferences calculated as the absolute value of the ∆ divided by the lower of the two mean protein values × 100, with % differences rounded to nearest 0.1%
^†P-values calculated by repeated measures ANOVA with Tukey post-test correction for multiple comparisons. All concentration values rounded to nearest 0.1 picogram
Instrument Abbreviations: 200 = Luminex 200; FM3D = FlexMap 3D; MPX = MagPix

ISSN: 1479-5876